1. Molecular Diagnostics As The Next Major Conceptual Transition
Jan Buck welcomes Dr. George Poste onto his show to discuss his uniquely rich view of the life science industry and highlights of his distinguished career. George tells us about his time at SmithKline Beecham, where he witnessed the dramatic transformations driven by molecular biology, genomics, and genetic engineering. Furthermore Jan and George look into molecular diagnostics and how they will allow us to transcend symptoms based empirical approaches and more rigorously characterize the underlying molecular pathologies.
2. Mapping the Human Genome, And The Innovator’s Dilemma In The Pharma Industry
On this latest edition of the Jan Buck Show, Dr. George Poste tells the story of one of the greatest broad-scale industry collaborations, the SNP Consortium (which became the HapMap Project). Aimed to study population genomics in relation with the analysis of susceptibility to disease and responsive to treatment, it harness the power of a large number of companies to create this body of data, furthering the research capabilities of all, while defraying risk and cost. Jan and George continue to discuss radical innovation, the innovator’s dilemma, and how it has applied to pharma and it’s blockbuster drugs.
3. Taking Out A Small Number of Pharmaceutical Manufacturing Plants Could Dislocate Medicine Supply For Large Numbers of the Global Population
Dr. George Poste tells the story of his involvement with the Antibioterrorism Task Force and the Office of the Secretary of Defense. When the DoD started looking at global infectious diseases – trying to measure the social, economic and military risk – they brought George in. Jan and George then discuss the post 9/11 era, and securing the medicine production and supply chain.
4. The Biodesign Institute, A Radical Experiment To Extract The Low Intensity Signal That May Be Indicative Of Disease
Dr. George Poste tells Jan Buck about his beginnings as veterinarian in the south of England, his escape from Europe to the United States in pursuit of greater scientific opportunity, and his recruiting at SmithKlein Beecham, taking genetic engineering technologies into the industry. George and Jan comment on the contribution the pharmaceutical industry has made towards human life. They continue to discuss his role in the creation of the Biodesign Institute of Arizona State University, where the life sciences are integrated with high level engineering, computing, and mathematical analysis. They measure hundreds or thousands of genes simultaneously, defining patterns of expression of multiple markers in the body, that may be indicative of disease.
5. A Look to the Future: Personalized Medicine, Consumer Driven Health, Synthetic Biology
Jan Buck and Dr. George Poste take a look at the blockbuster based business model of the Pharma industry, and how it might evolve in the years to come. They identify two emerging trends. First, is personalized medicine. Diagnostics and therapy will be increasingly linked. Clinical trials will become smaller, more effective, and cheaper to run. Second is consumer driven health, in which we all take greater responsibility for our own health. Finally, George tells us of his latest governmental responsibility, heading a new task force on synthetic biology – genetically engineering microorganisms to develop a new industrial ecology that can create alternative energy, novel materials, and molecular species that would otherwise be impossible or prohibitively expensive to produce.
This interview was conducted at the Nassau Inn, Princeton NJ, on December 10th, 2008
Featuring:
DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
Related Videos: